ming-hua hsu, ph. d. nuclear science and technology development center, nthu june 16, 2014 @ icnct...

36
Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing Nanodiamonds for Boron Neutron Capture Therapy

Upload: godfrey-garrison

Post on 27-Dec-2015

215 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Ming-Hua Hsu, Ph. D.Nuclear Science and Technology Development Center, NTHU

June 16, 2014

@ ICNCT 16, Helsinki, Funland

Development of Boron Containing Nanodiamonds

for Boron Neutron Capture Therapy

Page 2: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

2

OutlineOutline

1. Nanomedicine

2. Boron Containing Polmeric nanoparticle for

BNCT

PLA-PEOz-B-pin

PLA-PEOz-B-cage

3. Boron Containing Nanodiamonds for

BNCT

4. Boron Nanoparticles for BNCT

Page 3: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Nanomedicine: Nanotechnology to Medicine

Apply Nanotechnology:

•Maintain drug activity.

• Increase water solubility.

• Delivery drug by nanoparticle

• Increase drug efficiency

• Traceable or directable drug

NanomedicineUse of nano-materials in

medicine unique medical effects

Page 4: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

The Advantage of Nanoparticles

• High surface/volume ratio and good solubility

• Nanometer size lead to faster movement and easy entry into cell

• Nanoparticle vector can penetrate endothelial barriers to reach tumor

sites

nanoparticlesdrug

Page 5: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

The enhanced permeation and retention (EPR) effect

Nature Reviews Cancer 12, 39-50 (January 2012)

Page 6: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Micelle-based Drug Delivery System

The micelle must: (i) be small enough (∼10—200 nm) to effectively penetrate into tissue; (ii) be unrecognizable by the mononuclear phagocyte system (MPS) for a sufficient time to allow accumulation in target tissue; (iii) be eliminated from the organism either after degradation or dissolution;(iv) locate and interact with the target cells; (v) have tunable stability; (vi) improve the pharmacokinetic (PK) profile of the encapsulated drug cargo; (vii) possess high loading capacity; and (viii) be synthesized in a reproducible, facile method which is reasonably inexpensive

Page 7: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Development of BNCT Drug Deliver System Based on Polymeric Material PLA-PEOz

Page 8: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Polylactide, PLA

• Biocompatible• Biodegradable• Low immunogenicity• Good mechanical properties• FDA-approved for clinical use• Hydrophobic

OH

Ring opeing polymerization

O

O O

OLactide

O

O

OHm

PLA-OH

• Pseudopolypeptides• Adjustable• Biocompatible• Low immunogenicity• Stealth• FDA-approved as a food contact

agent• Hydrophilic

Polyoxazoline

Page 9: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Strategy of Copolymers Synthesis

OO

O

ON

O CH2

OHx

y

CH3

BO

O

OH

BO

O O

O

O

O

D,L-lactide

N

OEt

2-ethyl-2-oxazoline

pinacol combined 4-Benzylphenylboronic acid (Bpin)

ROP ROP

Bpin-PLA-PEOz-OH

ROP (Ring-Opening Polymerization)

Page 10: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Synthetic Scheme of Bpin-PLA-PEOz

BHO

HO OH

HO OH

MgSO4, THF

BO

O OH

O

OO O

Sn(Oct)2, toluene

BO

O

OO

O

O

OH

xMsCl

TEA,THF BO

O

OO

O

O

OMs

x

N

OEt

BO

O

OO

O

O

N

x O Et

OH

yMeCN

1.

2. KOH

4-hydroxylmethylphenylboronic acid

Bpin (Boronate ester initiator) D,L-lactide

Bpin-PLA Bpin-PLA-mesylate

2-ethyl-2-oxazoline

Bpin-PLA--PEOz

Page 11: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Characterizations of synthesized polymers

Table1 Characterizations of synthesized polymers

polymer Mna Polydispersity index (PDI)b

Yield (%) CMC (wt %)

Bpin-PLA 7218 1.21 98

Bpin-PLA-PEOz 14247 1.24 62 7×10-4

a Estimated by 1H NMR . b Estimated by GPC.

Page 12: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Boron Content of Bpin-PLA-PEOz micelle

Bpin-PLA-PEOz

• 6.06 ± 0.3 μg B/ml• 0.06

(boron/vehicle ratio)

Bpin-PLA-PEOz/PBAD

• 15.7 ± 0.6 μg B/ml• 0.15

(boron/vehicle ratio)

BHO

HO

PhMe, reflux, 16 h

O

BO

B

OBPTSA

Synthesis of Phenylboronic acid derivative (PBAD)

boron concentrations were determined by ICP-MS

Page 13: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Micelle Formation

Bpin-PLA-PEOz

PBAD (Phenyl boronic acid derivative)

The boron bearing diblock copolymers, once form the micelles, could load additional boron compounds, PBAD in this research.

Page 14: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Cell Viability by MTT assay

Cell viability after 48 h of incubation with the Bpin, PBAD, Bpin-PLA-PEOz and Bpin-PLA-PEOz/PBAD; error bars are mean ± SD (n=6). *Significantly different between PBAD and Bpin-PLA-PEOz/PBAD at the indicated concentration (p < 0.05).

Page 15: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Stability of Micelle in Storage Condition

0

50

100

150

200

0 20 40 60

Time (day)

Hydro

dyn

am

ic d

iam

ete

r(n

m)

0

50

100

150

200

0 20 40 60

Time (day)

Hydro

dyn

am

ic d

iam

ete

r(n

m)

Size alteration of PLA-PEOz (left) and Bpin-PLA-PEOz micelles (right)

The encapsulated micelles were deposited in 4 °C for 10days, 30days and 50 days. Then the micelles were analyzed by DLS to investigate the alteration of the particle size.

Page 16: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Nanomaterial strategies from the point-of-view of the cell

Page 17: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Hypoxia

Tissue hypoxia results from:1. O2 tension

low O2 partial pressure~ pulmonary diseases, high altitude

2. anemic hypoxiareduced ability of blood to carry O2 ~ anemia, CO poisoning

3. circulatory hypoxiareduced tissue perfusion ~ generalized or local

4. diffusional hypoxiaincrease diffusion distance

5. cytotoxic hypoxiaintoxication, cyanide poisoning

a state of decreased O2 availability below critical thresholds, thus restricting function of organs, tissue, or cells.

Page 18: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Tumor Hypoxia

• Solid tumor ~ highly heterogeneous~ exhibit oxygen tension, low pH, low glucose concentration

Kizaka-Kondoh et al. Cancer Sci. December, 2003

Page 19: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

O2 pressure (mmHg)

Normal tissues

Murine brain 60

Murine muscle 42

Bone marrow 40-50

Normal liver 55

Normal breast tissue 65

Normal cervix 48

Head and neck tissue 43

Tumors

Breast carcinoma 28

Solid tumors <2.5

Murine Fsall fibrosarcoma <5

Cancer of cervix <12

Head and neck cancers <10

Soft-tissue sarcomas <10

Oxygen Tensions in Various Tissue, Tumor

Normal tissue ~ 50-80 mmHg

Tumor < 10-30 mmHg

Page 20: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Nitroimdazoles derivatives

N N OH

NO2

N N

NO2

OHO

N N

NO2

OHF

N N

NO2

OHO

Br

N N

NO2

OH I

N N

NO2

O

I

O

OH

I NN

O2N

O

F

I NN

O2N

J. Nucl. Med. 2005

Euro. J. Nucl. Med. 1995

Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside

O N

N

OHOH

F18

O2N

A B C

FAZAB

O N

N

OHOH

F18

O2N

A B C

FAZAB

Page 21: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Bioreductive Metabolism of Nitroimidazole

NO2

-R.

R.

R-NO2H.

R-NO2H..

oxidative

damage

MEMBRANE

entry

efflux

NO2

OUT IN

1e

reduction

. H+

protonation

1e

DNA(-T) (ox)DNA+T-

2eR-NHOH R-NH2

H+

decomposition

H2O

disproportionation

R-NO2

O2O2-

futile

cycle

.

2eR- NO2R- NO2

-R- R-NO

hypoxia

HydrophilicCan Not penetrate membrane

Stock in cell

Page 22: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Size affects the biodistribution profile and therapeutical bechaviour of the system

Normal tissue

Hypoxia Tumour tissue

Dis-organized and leaky tumour endotelium

Defective lymphatic drainage

Lymph node

Normal vessels with tight endothelium

Intratumoural delivery of NPs

Nano-size penetration, cellular uptake, targeting

•active•passive

EPR-effectEnhanced permeation and retention effect

Hypoxia Targeting Nanodelivery

Page 23: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

BHO

HO OH

HO OH

MgSO4, THF

BO

O OH

O

OO O

Sn(Oct)2, toluene BO

O

OO

O

O

OH

x

MsCl

TEA,THF BO

O

OO

O

O

OMs

x

N

OEt

BO

O

OO

O

O

N

x O Et

OH

y

NNO2N OH

O

BO

O

OO

O

O

N

x O Et

O

y

N

O NNO2

MeCN1.

2. KOH

DMAP,DCC

Synthetic Scheme of Bpin-PLA-PEOz-NIm

Page 24: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Strategy of Copolymers Synthesis

OO

OO

O

Ox N

NH2

O Et

y

O

O

ROP

O

O

O

O

N

OEt

ROP

D,L-Lactide 2-Ethyl-2-oxazoline

closo-Dodecarborate with oxonium

Page 25: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Synthesis of (Bu4N)[B12H11O(CH2)2O(CH2)2OH]

= BH

O

O

OO

= B

NaH, THF

OH

2- 2-

(Bu4N) 2(Bu4N)NaOH

Reflux

Bu4NBr

Polymers Mw Mn PDI

B-PLA-OH 3175 2231 1.42

OO

OH Sn(Oct)2

D,L - Lactide

toluene

OO

OO

OH

O

O

x

Page 26: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Mesyl chloride dry TEA, dry THF

OO

OO

O

O

O

x S

O

O

CH3

2-ethyl-2-oxazoline KOH

OO

OO

O

O

x NNH2

O Et

y

Page 27: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

O (CH2)2 OO

O

N

OX

NH2

EtO

Y

B-PLA-PEOz-NH2

O (CH2)2

Hydrophobic part

Hydrophilic part

Page 28: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Nanodiamonds

• Chemically inert– however, can be surface-functionalized

• Biocompatible– low cytotoxicity

• Detectable – green fluorescence– by confocal and flow cytometry

Page 29: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

1. Tribology

2. Drug Delivery

3. Bioimaging

4. Tissue Engineering

5. Nanocomposites for Filler Materials

Mochalin, V. N. et al. Nat. Nanotechnol., 2011, 209, 11-23

Applications of Diamond Materials

Page 30: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Functionalized Nanodiamonds

Base on Organic Chemistry ~ Create New Nanodiamonds platform for Bioconjugate

Page 31: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Functionalized Nanodiamonds

Base on Organic Chemistry ~ Create New Nanodiamonds platform for Bioconjugate

O

O

O

COOH

O

O

O

OHOH

OH

OH

OH

OH

OH

SH

SH

SH

SH

SH

SH

1. HBr, HOAc, D

2. NaOH3. H2SO4

BH3, THF

NH2 NH2

S

OH+

S

NH2+

NH2

S SH OH -

H2O

- CO3-

- NH3

H+

-H2O

NH2 NH2

S

H+

Propose mechanism

N% C% H% S%

ND 3.411 84.729 1.011 0.287

ND-COOH 3.316 82.911 1.047 0.373

ND-OH 1.721 78.254 1.080 0.023

ND-SH 2.970 79.844 0.923 3.305

Accepted by ACS Applied Materials & Interfaces

Page 32: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

O1s

O1s

S2p

S2p

S2s

S2s

C1s

Survey CNT-SH

C1s

1200 1000 800 600 400 200 0

B.E. (eV)

Survey CNT-OH

1200 1000 800 600 400 200 0

S2pS2s

OKLL

O1s

B.E.(eV)

C1s

XPS of Thiolated Nanodiamonds and Carbon NanotubeXPS of Thiolated Nanodiamonds and Carbon Nanotube

Thiolated Nanodiamonds

180 175 170 165 160 155

-Csp3-SO2X

B.E.(eV)

-Csp3-SH

Thiolated Carbon Nanotube

Accepted by ACS Applied Materials & Interfaces

Page 33: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

TEM of Thiolated Nanodiamonds (100 nm) with Au-NPTEM of Thiolated Nanodiamonds (100 nm) with Au-NP

Accepted by ACS Applied Materials & Interfaces

Page 34: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

OH

O

O

HO

O

O

O

O

O

H

1. HNO3 / H2SO4

2. SOCl2

Bpin

Bpin

BpinBpin

Bpin

Bpin

BO

O OH

3. toluene, NEt3Bpin

Bpin :

Bpin O

O BO

O

Boron-containing NanodiamondsBoron-containing Nanodiamonds

Page 35: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

OH

O

O

HO

O

O

O

O

O

H

LiAlH4

THF

OHOH

OH

OH

OHHO

HO

HOO

O

= B= BH

OOB

OB

OB

OBBO

BO

BO

OO

NEt3, THF

Boron Cage-containing NanodiamondsBoron Cage-containing Nanodiamonds

Page 36: Ming-Hua Hsu, Ph. D. Nuclear Science and Technology Development Center, NTHU June 16, 2014 @ ICNCT 16, Helsinki, Funland Development of Boron Containing

Thank you very much for your attention.Taiwan is looking forward to seeing you in 2018!

18th International Congress on Neutron Capture Therapy in Taiwan in 2018Boron Neutron Capture Therapy – Best New Concept TherapyOctober 28th – November 2nd, 2018 | Taipei, Taiwan